Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance.
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Saxagliptin (Primary)
- Indications Diabetes mellitus; Glucose intolerance
- Focus Biomarker; Pharmacodynamics
- 16 Jan 2018 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 31 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.